Fat-burning claim fails
This article was originally published in The Tan Sheet
Executive SummaryClaims that Zylotrim weight-loss supplements more than doubles fat-burning enzyme activity are not supported and should be modified or discontinued, the Electronic Retailing Self-Regulation Program says. The Carlsbad, Calif.-based firm by the same name said it will modify that claim, and a second claim that 80 percent of each pound users lose is "pure body fat." In its March 23 decision, ERSP also determined the firm supported its claim that product users lost 200 percent more weight in combination with diet and exercise compared to subjects who dieted and exercised but did not use the product in two controlled clinical studies on the active ingredient, 3-acetyl-7-oxo-dehydroepiandrosterone. Zylotrim also provided a reasonable basis for the claim that the product is "clinically proven to help reduce body fat and weight.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.